Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

Al-Debasi, Tariq

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. [electronic resource] - Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society - 99-105 p. digital

Publication Type: Journal Article; Review

1319-4534

10.1016/j.sjopt.2017.02.008 doi